{"contentid": 488066, "importid": NaN, "name": "More positive data validate Lilly's big bet on mirikizumab", "introduction": "Positive results from a trial of Eli Lilly\u00e2\u0080\u0099s monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.", "content": "<p><span style=\"font-weight: 400;\">Positive results from a trial of Eli Lilly&rsquo;s (NYSE: LLY) monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.</span></p>\n<p><span style=\"font-weight: 400;\">The anti-interleukin (IL_-23p19 antibody is being developed for moderate to severe ulcerative colitis (UC), and data now show the Phase III LUCENT-1 study met its goals in this indication.</span></p>\n<p><span style=\"font-weight: 400;\">Lilly&rsquo;s competition is already racing ahead, with AbbVie&rsquo;s (NYSE: ABBV) anti-IL-23 antibody Skyrizi (risankizumab\u00e2\u0080\u0090rzaa) and Johnson &amp; Johnson&rsquo;s (NYSE: JNJ) Stelara (ustekinumab) making inroads in plaque psoriasis.</span></p>\n<p><span style=\"font-weight: 400;\">Meanwhile IL-17 blocker Cosentyx (secukinumab), from Swiss pharma major Novartis (NOVN: VX), is forecast to bring in more than $5 billion sales at its peak.</span></p>\n<p><span style=\"font-weight: 400;\">Lilly sees mirikizumab as a pivotal asset to compete in this space, having invested well over a billion dollars in an extensive trial program targeting immune-mediated disorders such as psoriasis and Crohn's disease.</span></p>\n<p><span style=\"font-weight: 400;\">In July 2020, the firm released </span><a href=\"https://www.thepharmaletter.com/article/lilly-s-mirikizumab-bests-cosentyx-in-phase-iii-psoriasis-trial\"><span style=\"font-weight: 400;\">positive data</span></a><span style=\"font-weight: 400;\"> which showed the candidate outperformed Cosentyx in psoriasis.</span></p>\n<h2><strong>Mirikizumab development</strong></h2>\n<p><span style=\"font-weight: 400;\">In LUCENT-1, mirikizumab met the primary endpoint of clinical remission at Week 12, compared to placebo, as well as all key secondary endpoints.</span></p>\n<p><span style=\"font-weight: 400;\">Secondary endpoints included reduced bowel urgency, clinical response, endoscopic remission, symptomatic remission and improvement in endoscopic histologic inflammation.</span></p>\n<p><span style=\"font-weight: 400;\">William Sandborn, gastroenterology chief at University of California San Diego, said: \"There is a continued need for additional treatments that can provide people living with ulcerative colitis relief from their most challenging symptoms.&rdquo;</span><span style=\"font-weight: 400;\"><br /></span></p>\n<p><span style=\"font-weight: 400;\">He added: \"Results of this study provide further clinical evidence of the potential for mirikizumab to become the first anti-IL-23p19 biologic for the treatment of ulcerative colitis.\"</span></p>\n<p><span style=\"font-weight: 400;\">The full LUCENT study results, including data from LUCENT-2 and LUCENT-3, will be disclosed at a future congress or publication.</span></p>", "date": "2021-03-17 14:31:00", "meta_title": NaN, "meta_keywords": "mirikizumab, positive, antibody, data, results, LUCENT-, competition, space, trial, NYSE, psoriasis, study, remission, colitis, ulcerative, clinical, Lilly", "meta_description": "Positive results from a trial of Eli Lilly\u00e2\u0080\u0099s monoclonal antibody mirikizumab raise the prospect of further competition in the gastrointestinal disorder space.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-17 14:14:35", "updated": "2021-03-17 14:32:39", "access": NaN, "url": "https://www.thepharmaletter.com/article/more-positive-data-validate-lilly-s-big-bet-on-mirikizumab", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "lilly-logo-big.jpg", "image2id": "lilly-logo-small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immunologicals", "topic_tag": "Drug Trial, Research", "geography_tag": "USA", "company_tag": "Eli Lilly, Johnson & Johnson, Novartis", "drug_tag": "Cosentyx, Mirikizumab, Stelara", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-17 14:31:00"}